2025年7月15日，Bioxcel Therapeutics Inc. 宣布，美国专利商标局已批准专利号18/600,419的申请。这一突破性专利覆盖了单剂量高达120微克的右美托咪定口用制剂，专用于治疗精神分裂症或双相情感障碍相关急性激越的特定患者亚群。新专利与IGALMI推荐剂量方案完美契合，成为该药物的第14个橙皮书列名专利。专利有效期至2043年1月12日，未来可能基于调整延长。此进展标志着公司在创新疗法领域的重要里程碑，强化了Igalmi的知识产权护城河。
免责声明：本新闻内容由人工智能生成，仅供信息参考，不构成任何财务、投资或法律建议。原始信息由Bioxcel Therapeutics Inc.通过官方渠道发布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.